SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
Status:
Terminated
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving SGN-30 together with combination chemotherapy
works in treating patients with newly diagnosed anaplastic large cell lymphoma. Monoclonal
antibodies, such as SGN-30, can block cancer growth in different ways. Some block the ability
of cancer cells to grow and spread. Others find cancer cells and help kill them or carry
cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop
the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Giving SGN-30 together with combination chemotherapy may kill more cancer cells